ClinicalTrials.gg
Status unknownNCT03535415Updated Nov 23, 2018

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation

A Phase 3 interventional study of Recombinant Human Growth Hormone Injection (rhGH) in Dwarfism, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Status unknown at 12 sites in China. Open to participants aged 2 Years to 14 Years. Per ClinicalTrials.gov, last updated 2018-11-23.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
2 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing Human Growth Hormone in Dwarfism — none open to participants now, 1 under way, none of them phase 3. Human Growth Hormone · Dwarfism.

Planned enrollment
8th of 15
68 · median 68
Started
2018
with 1 other
Phase 3
4 of 15
none open now
Registered
15th of 15
by date
Lead sponsor
3 of 15
Changchun GeneScience Pharmaceutical Co., Ltd.

Among the 15 studies testing Human Growth Hormone in Dwarfism, this one is the 8th largest by planned enrollment, is one of 2 that started in 2018, is one of 4 in phase 3, and was the 15th registered.

Dwarfism

99 studies on the registry are indexed under Dwarfism; 12 are open to participants now.

Browse Dwarfism studies →

Open to participants now

None of the 15 studies testing Human Growth Hormone in Dwarfism is open now. The open studies under Dwarfism, anywhere →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 7 Dwarfism studies recruiting now, 1 sets no upper age limit and 5 stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 2 Years to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing Human Growth Hormone in Dwarfism as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of recombinant human growth hormone injection in short stature children due to chronic kidney disease before transplantation.

03

Conditions studied

  • Dwarfism

Browse trials for

04

Who can participate

Ages eligible
2 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed of the subjects or the legal guardian.
  • Subjects and guardian are willing and able to cooperate to complete scheduled visits,treatment plans and laboratory tests and other procedures.
  • Diagnosed as chronic kidney disease.
  • (GFR) \<75ml/per min/1.73m2.
  • After the treatment and adjustment of hypertension, anemia, metabolic acidosis, malnutrition, renal osteopathy, hypothyroidism, etc..
  • Chronological age: ≥2years and ≤14years.
  • Height Standard Deviation Score(HtSDS) ≤-2SD for chronological age.
  • Bone age: girls≤10 years; boys≤11years.
  • Pre-pubertal (Tanner Stage I ) patients.
  • No history of growth hormone treatment.

Exclusion criteria

Exclusion Criteria:

  • Subjects with abnormal liver functions.
  • Subjects positive for , HbsAg or HbeAg in Hepatitis B virus tests.
  • After adjustment heart function,Cardiac (EF) \<50%.
  • Subjects with highly allergic constitution or allergy to proteins or product or its .
  • Subjects with systemic chronic disease or general infection or mental disease.
  • Subjects with diabetes or impaired fasting glucose.
  • Subjects with tumor or potential tumor.
  • Subjects who are using or .
  • Other causes for growth retardation.
  • Inability to obtain accurate height measurements.
  • Subjects who took part in other clinical trials within 3 months.
  • Concomitant administration of other treatment that may have an effect on growth within 3 months.
  • Other conditions which are unsuitable for this study in the opinion of the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    rhGH Injection

    rhGH 0.05mg/kg/d by subcutaneous injection

    Drug: Recombinant Human Growth Hormone Injection (rhGH)

  • No intervention
    Non-treatment control group

    Only follow-up without treatment

Interventions

06

What researchers measure

Primary outcomes

  1. The change of height standard deviation score of chronological age before and after treatment (ΔHT SDS)

    Time frame: 52 weeks,104 weeks

Secondary outcomes

  1. Growth velocity

    365.25\*(height at the time of assessment -height at baseline)/duration of treatment(days)

    Time frame: 12 months, 24 months

  2. Bone maturation ( bone age/ chronological age: BA/CA)

    Time frame: 12 months, 24 months

  3. IGF-1 (Insulin-like growth factor 1) SDS

    Time frame: 12 months, 24 months

  4. IGF-1/IGFBP-3 molar ratio

    Time frame: 12 months, 24 months

07

Study locations

12 of 12 sites recruiting
  • Fuzhou general hospital of Nanjing military command
    Fuzhou, Fujian, China
    Recruiting
    • Zihua Yu · Contact
  • The first affiliated hospital of zhengzhou university
    Zhengzhou, Henan, China
    Recruiting
    • Jianjiang Zhang · Contact
  • Tongji medical college huazhong university of science & technology
    Wuhan, Hubei, China
    Recruiting
    • Jianhua Zhou · Contact
  • Shengjing hospital of chian medical university
    Shenyang, Liaoning, China
    Recruiting
    • Yubin Wu · Contact
  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai, China
    Recruiting
    • Yufeng Li · Contact
  • The Children's Hospital ,Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
    • Jianhua Mao · Contact
  • Beijing Children's Hospital, Capital Medical University
    Beijing, China
    Recruiting
    • Ying Shen · Contact
  • Children's hospital capital institute of pediatrics
    Beijing, China
    Recruiting
    • Chaoying Chen · Contact
  • Peking university first hospital
    Beijing, China
    Recruiting
    • Huijie Xiao · Contact
  • Children's hospital of Chongqing medical university
    Chongqing, China
    Recruiting
    • Mo Wang · Contact
  • Children's Hospital of Fudan University
    Shanghai, China
    Recruiting
    • Hong Xu · Contact
  • Children's Hospital of Shanghai
    Shanghai, China
    Recruiting
    • Wenyan Huang · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2018 (actual). Primary completion is estimated for Sep 2020, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2018
First posted
May 24, 2018
StartActual
Jun 25, 2018
Primary completionEst.
Sep 2020
CompletionEst.
Sep 2021
Last update
Nov 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03535415
Collaborators
Children's Hospital of Fudan University, Beijing Children's Hospital, Shanghai Children's Hospital, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, The Children's Hospital of Zhejiang University School of Medicine, Children's Hospital of The Capital Institute of Pediatrics, Peking University First Hospital, Fuzhou General Hospital, The First Affiliated Hospital of Zhengzhou University, Shengjing Hospital, Children's Hospital of Chongqing Medical University, Tongji medical college huazhong university of science & technology
Responsible party
Sponsor
First posted
May 24, 2018
Start date
Jun 25, 2018
Primary completion
Sep 2020 (estimated)
Completion
Sep 2021 (estimated)
Last update
Nov 23, 2018

Study contacts

Xiaohua Feng
Contact
fengxiaohua@gensci-china.com
13610794989
Hong Xu, PhD
principal investigator · Children's Hospital of Fudan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion